Therapy Detail

Therapy Name HM-3
Therapy Description

HM-3 is a synthetic peptide derived from endostatin, which targets integrin alpha v beta 3, possibly resulting in inhibition of angiogenesis and tumor growth (PMID: 27633584).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
HM-3 HM-3 is a synthetic peptide derived from endostatin, which targets integrin alpha v beta 3, possibly resulting in inhibition of angiogenesis and tumor growth (PMID: 27633584).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colon cancer not applicable HM-3 Preclinical - Cell line xenograft Actionable In a preclinical study, a colon cancer cells treated with HM-3 demonstrated reduced cell migration in culture and inhibition of tumor growth in xenograft models (PMID: 27633584). 27633584
Clinical Trial Phase Therapies Title Recruitment Status